Combination anticancer nanopreparations of novel proapoptotic drug and siRNA The current project is an integral part of our CCNE proposal which aims to develop, characterize in vitro, test in animal models, and scale up in an industrial setting a broad set of novel multifunctional nanocarriers for targeted delivery of various drugs including DNA, siRNA, and diagnostic agents to solid tumors in vivo for the purposes of cancer therapy and diagnostics, especially for multidrug resistant (MDR) tumors. Within the general program, this proposal will cover a combination nanopreparations containing a novel, powerful proapoptotic agent, siRNA [to downregulate cancer cell defense mechanisms (such as Pgp)], and Tumor necrosis factor-Related Apoptosis-inducing Ligand (TRAIL), a cytokine of the TNFa family, a novel promising, selective anti-cancer agent. This combination micellar preparation will be additionally modified with a tumor-specific targeting antibody (for systemic administration) or with the cell-penetrating TAT peptide (TATp) for intratumoral administration). Our proposal is based on several interrelated challenges. First, effective therapy of a cancer, especially in the case of MDR tumors still represents an important medical need. Second, many newly discovered or synthesized proapoptotic anticancer agents, which could serve as an effective means to treat cancer in combination with TRIAL by upregulating apopototic mechanisms in cancer cells, cannot now serve as practical drugs because of their poor solubility and low stability in vivo. Third, siRNAs (that downregulate tumor defense mechanisms) have very low stability in the body and multiple delivery problems. We propose to overcome these challenges by formulating a combination of new agents into self-assembling pharmaceutical nanocarriers (lipid-core micelles) specifically targeted to and into cancer cells. Such formulations will allow for an efficient solubilization of a poorly soluble proapoptotic drug, stabilization of the drug or a siRNA in the body, and their efficient co-delivery together with TRIAL into targeted tumors. Thus, within the overarching organizing framework, this proposal will provide multifunctional micellar combinations of nanopreparations to specifically deliver a proapoptotic drug, a siRNA, and TRIAL to various tumors, particularly, to MDR tumors.

Public Health Relevance

This project addresses a well-known limitation on tumor drug treatment and imaging of a diagnosed tumor: the inability to get sufficient anti-cancer drug to a well-defined target. This project's completion will generate effective drug carriers that will make possible clinical application of known anti-cancer agents and provide the means for the rapid clinical development of highly effective therapeutic anti-cancer agents.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center--Cooperative Agreements (U54)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-GRB-S)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Northeastern University
United States
Zip Code
Jhaveri, Aditi; Deshpande, Pranali; Pattni, Bhushan et al. (2018) Transferrin-targeted, resveratrol-loaded liposomes for the treatment of glioblastoma. J Control Release 277:89-101
Wang, Tao; Narayanaswamy, Radhika; Ren, Huilan et al. (2018) Phage-derived protein-mediated targeted chemotherapy of pancreatic cancer. J Drug Target 26:505-515
Kumar, Gaurav; Goldberg, S Nahum; Gourevitch, Svetlana et al. (2018) Targeting STAT3 to Suppress Systemic Pro-Oncogenic Effects from Hepatic Radiofrequency Ablation. Radiology 286:524-536
Upponi, Jaydev R; Jerajani, Kaushal; Nagesha, Dattatri K et al. (2018) Polymeric micelles: Theranostic co-delivery system for poorly water-soluble drugs and contrast agents. Biomaterials 170:26-36
Petrenko, Valery A; Gillespie, James W (2017) Paradigm shift in bacteriophage-mediated delivery of anticancer drugs: from targeted 'magic bullets' to self-navigated 'magic missiles'. Expert Opin Drug Deliv 14:373-384
van de Ven, Anne L; Tangutoori, Shifalika; Baldwin, Paige et al. (2017) Nanoformulation of Olaparib Amplifies PARP Inhibition and Sensitizes PTEN/TP53-Deficient Prostate Cancer to Radiation. Mol Cancer Ther 16:1279-1289
Pattni, Bhushan S; Jhaveri, Aditi; Dutta, Ivy et al. (2017) Targeting energy metabolism of cancer cells: Combined administration of NCL-240 and 2-DG. Int J Pharm 532:149-156
Gillespie, James W; Wei, Lixia; Petrenko, Valery A (2016) Selection of Lung Cancer-Specific Landscape Phage for Targeted Drug Delivery. Comb Chem High Throughput Screen 19:412-22
Singh, Amit; Xu, Jing; Mattheolabakis, George et al. (2016) EGFR-targeted gelatin nanoparticles for systemic administration of gemcitabine in an orthotopic pancreatic cancer model. Nanomedicine 12:589-600
Patel, Niravkumar R; Piroyan, Aleksandr; Nack, Abbegial H et al. (2016) Design, Synthesis, and Characterization of Folate-Targeted Platinum-Loaded Theranostic Nanoemulsions for Therapy and Imaging of Ovarian Cancer. Mol Pharm 13:1996-2009

Showing the most recent 10 out of 86 publications